Navigation Links
Xanodyne Announces New Executive Team Members
Date:7/13/2009

NEWPORT, Ky., July 13 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced the appointment of three new members to its executive management team. Joining the company are Natasha Giordano, Chief Commercial Officer; Rita O'Connor, Chief Financial & Information Officer; and Peter Wentworth, Senior Vice President, Human Resources.

Commenting on these appointments, CEO Michael J. Valentino said, "I am excited to welcome Natasha, Rita, and Peter to the Xanodyne management team. Each of them brings a diverse and proven track record of building and leading high growth organizations within the pharmaceutical industry. Their collective experience should contribute significantly to the anticipated rapid growth and commercial success of our company."

Ms. Giordano has more than 25 years of experience in the healthcare and pharmaceutical industry and most recently served as President Americas at Cegedim Dendrite, a global sales and marketing solutions and information company specializing in the pharmaceutical industry. Her depth of experience includes senior leadership positions in general management, marketing, compliance, and sales at major pharmaceutical companies including Pfizer and Parke-Davis.

Ms. O'Connor joins Xanodyne from NPS Pharmaceuticals where she served as Vice President, Finance. Previously, she was Chief Financial Officer and Treasurer at Adams Respiratory Therapeutics. With nearly 20 years of finance and accounting experience in the pharmaceutical industry, O'Connor is a certified public accountant and has held leadership positions at Schering-Plough and Deloitte & Touche. She also serves on the Board of Directors at the Essential Group Inc.

Mr. Wentworth has extensive experience within the field of human resources, including more than 25 years working in global healthcare and consumer products industries. Most recently he was Executive Vice President, Human Resources at Adams Respiratory Therapeutics. Wentworth is a seasoned business leader, who has held a broad range of positions at major global companies such as Pfizer, Warner-Lambert, and PepsiCo.

About Xanodyne
Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.


'/>"/>
SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2009 Earnings Release and Conference Call
2. Jesup & Lamont Announces Presenting LifeTech Companies and Former FDA Commissioner at Annual Growth Stock & National Sales Conference
3. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
6. Mirixa Corporation Announces Key New Hires
7. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
8. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
10. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):